Press monitoring
FDA: No significant impact from test of modified mosquitoes
14.3.2016 | Press monitoring
A field trial releasing genetically modified mosquitoes in the Florida Keys would not harm humans or the environment, according to documents released Friday by the U.S. Food and Drug Administration. The agency's Center for Veterinary Medicine released a preliminary finding of no significant impact for the field trial on a method that aims to...
Newly discovered bacteria can eat plastic bottles
11.3.2016 | Press monitoring
A team of Japanese scientists has found a species of bacteria that eats the type of plastic found in most disposable water bottles. The discovery, published Thursday in the journal Science, could lead to new methods to manage the more than 50 million tons of this particular type of plastic produced globally each year. The plastic found in water...
Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
10.3.2016 | Press monitoring
Oslo 10 March 2016 - Targovax has conducted a predetermined interim analysis of the TG01 Phase I/II trial, indicating promising 1-year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer.
First European Patients Enroll in Medtronic International Lung Cancer Study
10.3.2016 | Press monitoring
DUBLIN - March 10, 2016 - Committed to technologies that assist in the goal of reducing lung cancer morbidity worldwide, Medtronic (NYSE: MDT) today announced European enrollment in the NAVIGATE clinical trial. This 2,500-patient international study will assess the long-term impact of its superDimension(TM) navigation system as an aid in early...
Researchers report cell-to-cell movement of mitochondria through a graft junction
9.3.2016 | Press monitoring
A team of researchers with Rutgers University has found an example via experimentation, of cell-to-cell movement of mitochondria through a graft junction of two tobacco species. In their paper published in PNAS, the team describes their experiments with grafting tobacco plants and what they learned about cells swapping mitochondria during the...
Growth of functional breast tissue spawns a new weapon in cancer research
7.3.2016 | Press monitoring
Current approaches to breast cancer research have their limitations when it comes to observing its behavior in live human tissue. There is something to be gained by studying cells in mice and the lab, but these methods still don't paint a complete picture. Researchers have now built a hydrogel scaffold that mimics the environment found within...
Supercomputer probes depths of biofuel\'s biggest barrier
4.3.2016 | Press monitoring
Ask a biofuel researcher to name the single greatest technical barrier to cost-effective ethanol, and you're likely to receive a one-word response: lignin. Cellulosic ethanol—fuel derived from woody plants and waste biomass—has the potential to become an affordable, renewable transportation fuel that rivals gasoline, but lignin, one of the most...
Glow-in-the-dark bacterial lights could illuminate shop windows
2.3.2016 | Press monitoring
Bacteria may light up the future. Glowee, a start-up company based in Paris, France, is developing bioluminescent lights to illuminate shop fronts and street signs. After a successful demo in December, Glowee has launched its first product – a bacteria-powered light that glows for three days. The company is now working on lights that will glow...
Actelion emphasizes commitment to advance research and care in rare diseases
29.2.2016 | Press monitoring
ALLSCHWIL, SWITZERLAND - 29 February 2016 - Today, on Rare Disease Day 2016, patients, their families and caregivers, patient organizations, medical professionals, politicians and researchers are coming together to raise awareness for what living with a rare disease means for those affected and for their families.
Summit Therapeutics Supports Ninth Annual Rare Disease Day
29.2.2016 | Press monitoring
Oxford, UK, 29 February 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces today its support for the ninth annual Rare Disease Day on 29 February 2016. The Rare Disease Day 2016 theme,...
